We are live on
!
Find out more
MWNA
Marshall Wace North America Portfolio holdings
AUM
$23.5B
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+9.94%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$24.1B
AUM Growth
-$134M
(-0.56%)
Cap. Flow
-$2.11B
Cap. Flow
% of AUM
-8.76%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
1,984
New
527
Increased
347
Reduced
445
Closed
587
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$157M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$135M |
| 3 |
Salesforce
CRM
|
+$135M |
| 4 |
IBM
IBM
|
+$130M |
| 5 |
Dell
DELL
|
+$114M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$313M |
| 2 |
Apple
AAPL
|
+$207M |
| 3 |
Intel
INTC
|
+$183M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$159M |
| 5 |
Centene
CNC
|
+$152M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.31% |
| 2 | Technology | 17.95% |
| 3 | Communication Services | 13.61% |
| 4 | Consumer Discretionary | 12.67% |
| 5 | Financials | 8.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
RTX Corp
RTX
$301B
| $7.69M | 0.03% |
90,151
-107,544
| -54% | -$9.05M |
|
427
Xenon Pharmaceuticals
XENE
$6.12B
| $7.66M | 0.03% |
+411,259
| New | +$7.58M |
|
|
SAFM
428
DELISTED
Sanderson Farms Inc
SAFM
| $7.65M | 0.03% |
40,693
+33,028
| +431% | +$5.56M |
|
|
CORZ
429
DELISTED
Core Scientific, Inc. Common Stock
CORZ
| $7.62M | 0.03% |
+775,000
| New | +$7.64M |
|
430
Dynatrace
DT
$14.2B
| $7.61M | 0.03% |
130,302
-125,025
| -49% | -$6.53M |
|
431
HubSpot
HUBS
$10.5B
| $7.59M | 0.03% |
13,025
+9,392
| +259% | +$4.9M |
|
432
PubMatic
PUBM
$810M
| $7.56M | 0.03% |
+193,412
| New | +$8.05M |
|
|
PTR
433
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
| $7.54M | 0.03% |
153,720
+108,823
| +242% | +$4.42M |
|
|
WBA
434
DELISTED
Walgreens Boots Alliance
WBA
| $7.51M | 0.03% |
142,717
+84,385
| +145% | +$4.54M |
|
435
CME Group
CME
$94.8B
| $7.44M | 0.03% |
34,997
-134,839
| -79% | -$28.5M |
|
436
Hamilton Lane
HLNE
$5.57B
| $7.41M | 0.03% |
81,282
-40,455
| -33% | -$3.66M |
|
437
W.P. Carey
WPC
$16.4B
| $7.37M | 0.03% |
100,852
+78,550
| +352% | +$5.75M |
|
438
CrowdStrike
CRWD
$218B
| $7.34M | 0.03% |
116,772
-566,092
| -83% | -$30.5M |
|
|
SPAQ
439
DELISTED
Spartan Acquisition Corp. III
SPAQ
| $7.33M | 0.03% |
+750,000
| New | +$7.38M |
|
|
NSLR
440
Neostellar Capital Corp
NSLR
$254M
| $7.31M | 0.03% |
542,129
+454,233
| +517% | +$5.9M |
|
441
Thryv Holdings
THRY
$108M
| $7.3M | 0.03% |
204,069
+189,703
| +1,320% | +$5.36M |
|
442
Kontoor Brands
KTB
$4.26B
| $7.27M | 0.03% |
+128,839
| New | +$7.9M |
|
443
Purple Innovation
PRPL
$41.7M
| $7.26M | 0.03% |
+11,004
| New | +$8.44M |
|
444
Century Therapeutics
IPSC
$361M
| $7.25M | 0.03% |
+247,251
| New | +$6.27M |
|
|
PDAC
445
DELISTED
Peridot Acquisition Corp.
PDAC
| $7.2M | 0.03% |
590,908
-71,070
| -11% | -$764K |
|
446
Microchip Technology
MCHP
$46B
| $7.18M | 0.03% |
+95,892
| New | +$7.31M |
|
447
Cemex
CX
$16.3B
| $7.16M | 0.03% |
851,897
-285,975
| -25% | -$2.27M |
|
448
Scholar Rock
SRRK
$6.44B
| $7.13M | 0.03% |
246,541
-182,560
| -43% | -$5.59M |
|
449
Quest Diagnostics
DGX
$26.3B
| $7.12M | 0.03% |
53,989
+40,573
| +302% | +$5.31M |
|
|
VISN
450
Vistance Networks Inc
VISN
$2.52B
| $7.1M | 0.03% |
333,352
-113,236
| -25% | -$2.11M |
|
Similar funds
TGHSA
PAM
HB
MWA
3SCA
HFCIV
DVC
NAM
Marshall Wace North America's Q2 2021 Portfolio in Review
As of Q2 2021, Marshall Wace North America held 1,984 positions worth $24.1B, down 0.56% from $24.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Marshall Wace North America withdrew a net $2.11B in Q2 2021, closing 587 positions and reducing 445 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $119M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Marshall Wace North America opened a new position in Syneos Health, Inc. Class A Common Stock worth $83.7M.
- Marshall Wace North America's largest Q2 2021 buy was Syneos Health, Inc. Class A Common Stock: 935,304 shares worth $83.7M.
- Marshall Wace North America added most to Johnson & Johnson in Q2 2021, an estimated $157M increase.
- Marshall Wace North America's biggest Q2 2021 reduction was Microsoft, cutting an estimated $313M.
- Marshall Wace North America fully exited State Street SPDR S&P 500 ETF Trust in Q2 2021, selling an estimated $119M.
- Marshall Wace North America's ten largest holdings make up 24% of its $24.1B portfolio in Q2 2021.
- Marshall Wace North America opened 527 new positions and closed 587 in Q2 2021.
- Marshall Wace North America's portfolio value fell 0.56% quarter-over-quarter to $24.1B.
Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.